X

Trial Profile

An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Neuroendocrine tumours; Pancreatic cancer
Focus Adverse reactions; Registrational
Sponsors Novartis Pharma

Most Recent Events

19 May 2016 Results published in the Targeted Oncology
17 Nov 2012 Planned number of patients changed from 200 to 400 as reported by EudraCT (Parent trial: EudraCT2010-023032-17).
07 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com